104
Participants
Start Date
February 13, 2017
Primary Completion Date
October 31, 2019
Study Completion Date
November 22, 2022
lenvatinib
4 mg capsules
pembrolizumab (200 mg)
30-minute intravenous infusion
Icahn School of Medicine Mount Sinai, New York
Hôpital Timone, Marseille
IRCCS Istituto Clinico Humanitas, Milan
Mercy Medical Center, Baltimore
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario 12 de Octubre, Madrid
CHU Toulouse, Toulouse
Hôpital Haut-Levêque Centre médico-chirurgical Magellan, Pessac
Centre Eugène Marquis de Rennes, Rennes
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario Marqués de Valdecilla, Santander
BRCR Global Texas, Edinburg
Ronald Reagan UCLA Medical Center, Santa Monica
California Pacific Medical Center (CPMC), San Francisco
Massachusetts General Hospital, Boston
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna
Eisai Trial Site 2, Kashiwa
Eisai Trial Site 4, Kawasaki
Eisai Trial Site 3, Sayama
Eisai Trial Site 1, Chuo-ku
Republican Clinical Oncology Dispensary, Ufa
St. Petersburg City Clinical Oncology Dispansery, Saint Petersburg
S.I. Russian Oncological Research Center n.a. N. N. Blokhin RAMS, Moscow
Altay Regional Oncology Dispensary, Barnaul
Hospital Infanta Cristina de Badajoz, Badajoz
Royal Free Hospital, London
Merck Sharp & Dohme LLC
INDUSTRY
Eisai Co., Ltd.
INDUSTRY